Burning Rock Biotech Ltd. (BNR)
|Net Income (ttm)||-72.16M|
|Trading Day||April 16|
|Day's Range||28.28 - 30.44|
|52-Week Range||18.64 - 39.75|
Burning Rock's Liquid Biopsy Assay Achieved Strong Performance in the FDA-led SEQC2 Study, with Results Published on ...
GUANGZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that its liquid biopsy assay has achieved strong performa...
GUANGZHOU, China, March 10, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS)...
Burning Rock Announces Preliminary Fourth Quarter and Full Year 2020 Results and Schedules Earnings Release on March ...
GUANGZHOU, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) ...
Burning Rock (BNR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Burning Rock Biotech went public in the U.S. in June 2020. The firm provides a range of early detection and therapy selection testing services in China.
OncoCyte's stock soars after licensing deal with China-based company, days after insiders acquired shares
Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement...
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for ... [Read more...]
Diagnostics & Research
|IPO Date |
Jun 12, 2020
|Stock Exchange |
|Ticker Symbol |
In 2020, BNR's revenue was 429.90 million, an increase of 12.64% compared to the previous year's 381.68 million. Losses were -407.24 million, 140.7% more than in 2019.
According to 3 analysts, the average rating for BNR stock is "Strong Buy." The 12-month stock price forecast is 23.18, which is a decrease of -21.58% from the latest price.